Search
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalIt is developed by Insmed and is currently under phase I of the clinical trial.
alpha-Hydroxy glycineamide
go.drugbank.com/drugs/DB06568ExperimentalAlpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid
RGX-181
go.drugbank.com/drugs/DB17942ExperimentalDeveloped by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072]
Tepoxalin
go.drugbank.com/drugs/DB11466ExperimentalVet approvedIt is primarily used to reduce inflammation and relief of pain caused by musculoskeletal disorders such as hip dysplasia and arthritis.
BBM-H803
go.drugbank.com/drugs/DB17700InvestigationalBBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed.
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalDeveloped by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153]
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781InvestigationalHu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated
Pentaglobin
go.drugbank.com/drugs/DB15865Investigational[A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]
Dihydroxyacetone
go.drugbank.com/drugs/DB01775ExperimentalIt is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem]
Atigliflozin
go.drugbank.com/drugs/DB21394InvestigationalAtigliflozin is under investigation in clinical trial NCT00361738 (Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment).